文献速递神经肿瘤小儿神经外科与脑积水

新诊断弥漫性内生性脑桥胶质瘤患者手术活检的前瞻性可行性与安全性评估

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
PubMed 文献 · Neuro Oncol · 2018-01-01

DIPG-BATS 研究在 23 家机构纳入 53 例新诊断弥漫性内生性脑桥胶质瘤患者,50 例行手术活检,无操作相关死亡,2 例出现术中 3 级毒性(呼吸暂停 1 例、高血压 1 例),1 例遗留未完全恢复的神经功能缺损;50 例中 46 例获得足够组织完成研究检测(92%,两阶段精确二项 90% CI:83%-97%)。结论认为手术活检技术上可行、风险可接受,可提供指导治疗决策的生物学数据。

要点

  • 53 例入组、50 例行活检,无操作相关死亡。
  • 术中 2 例 3 级毒性:呼吸暂停 1 例、高血压 1 例。
  • 1 例出现未完全恢复的左侧偏瘫。

核心结论

  • 手术活检技术上可行、风险可接受,可提供指导治疗决策的生物学数据。

研究设计与样本

  • DIPG-BATS 前瞻性研究,纳入临床特征和影像表现符合新诊断弥漫性内生性脑桥胶质瘤的受试者。
  • 入组后、确定性治疗前进行手术活检,所有受试者接受常规外照射放疗联合贝伐珠单抗。
  • 根据 O6-甲基鸟嘌呤-DNA甲基转移酶状态和表皮生长因子受体表达,分层接受贝伐珠单抗联合厄洛替尼或替莫唑胺、两者联合或两者均不联合。
  • 53 例患者来自 23 家机构,其中 50 例行活检;中位年龄 6.4 岁,男性 24 例、女性 29 例。

主要发现

  • 手术活检按指定技术进行,无死亡归因于该操作。
  • 2 例受试者在操作过程中出现 3 级毒性(呼吸暂停 1 例、高血压 1 例)。
  • 1 例受试者出现未完全恢复的神经功能缺损(左侧偏瘫)。
  • 50 例活检肿瘤中 46 例提供足够组织完成研究检测(92%,两阶段精确二项 90% CI:83%-97%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. METHODS: Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment. RESULTS: Fifty-three patients were enrolled at 23 institutions, and 50 underwent biopsy. The median age was 6.4 years, with 24 male and 29 female subjects. Surgical biopsies were performed with a specified technique and no deaths were attributed to the procedure. Two subjects experienced grade 3 toxicities during the procedure (apnea, n = 1; hypertension, n = 1). One subject experienced a neurologic deficit (left hemiparesis) that did not fully recover. Of the 50 tumors biopsied, 46 provided sufficient tissue to perform the study assays (92%, two-stage exact binomial 90% CI: 83%-97%). CONCLUSIONS: Surgical biopsy of DIPGs is technically feasible, associated with acceptable risks, and can provide biologic data that can inform treatment decisions.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018. PMID: 29741745. doi:10.1093/neuonc/noy070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。